Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael R Jordan

Showing results (61-70 of 103) with videos related to

Pageof 11
Sort By:
The Lancet. HIV|June 21, 2025
Lenacapavir-associated drug resistance: implications for scaling up long-acting HIV pre-exposure prophylaxisGert van Zyl, Mateo Prochazka, Heather-Marie Ann Schmidt, et al.
Plos One|December 2, 2016
Assessment of the World Health Organization's HIV Drug Resistance Early Warning Indicators in Main and Decentralized Outreach Antiretroviral Therapy Sites in NamibiaNicholus Mutenda, Alexandra Bukowski, Anne-Marie Nitschke, et al.
The Lancet. HIV|October 2, 2015
Effectiveness and cost-effectiveness of potential responses to future high levels of transmitted HIV drug resistance in antiretroviral drug-naive populations beginning treatment: modelling study and economic analysisAndrew N Phillips, Valentina Cambiano, Alec Miners, et al.
The Lancet. HIV|September 16, 2023
Checklist for studies of HIV drug resistance prevalence or incidence: rationale and recommended useLawrence Mbuagbaw, Cristian Garcia, Bluma Brenner, et al.
Plos One|March 20, 2013
Medication possession ratio associated with short-term virologic response in individuals initiating antiretroviral therapy in NamibiaSteven Y Hong, Logan Jerger, Anna Jonas, et al.
The Journal of Infectious Diseases|November 17, 2020
Clinical Impact of Pretreatment Human Immunodeficiency Virus Drug Resistance in People Initiating Nonnucleoside Reverse Transcriptase Inhibitor-Containing Antiretroviral Therapy: A Systematic Review and Meta-analysisSilvia Bertagnolio, Lucas Hermans, Michael R Jordan, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 8, 2015
Population-based surveillance of HIV drug resistance emerging on treatment and associated factors at sentinel antiretroviral therapy sites in NamibiaSteven Y Hong, Anna Jonas, Michael DeKlerk, et al.
AIDS (London, England)|August 8, 2013
Averted HIV infections due to expanded antiretroviral treatment eligibility offsets risk of transmitted drug resistance: a modeling studyBrooke E Nichols, Kim C E Sigaloff, Cissy Kityo, et al.
AIDS (London, England)|June 1, 2019
Increasing levels of pretreatment HIV drug resistance and safety concerns for dolutegravir use in women of reproductive ageSeth Chekata Inzaule, Michael R Jordan, Amandine Cournil, et al.
Plos One|February 2, 2017
High Levels of Transmitted HIV Drug Resistance in a Study in Papua New GuineaEvelyn Lavu, Ellan Kave, Euodia Mosoro, et al.
Pageof 11

Showing results (61-70 of 103) with videos related to

Sort By:
Pageof 11
The Lancet. HIV|June 21, 2025
Lenacapavir-associated drug resistance: implications for scaling up long-acting HIV pre-exposure prophylaxisGert van Zyl, Mateo Prochazka, Heather-Marie Ann Schmidt, et al.
Plos One|December 2, 2016
Assessment of the World Health Organization's HIV Drug Resistance Early Warning Indicators in Main and Decentralized Outreach Antiretroviral Therapy Sites in NamibiaNicholus Mutenda, Alexandra Bukowski, Anne-Marie Nitschke, et al.
The Lancet. HIV|October 2, 2015
Effectiveness and cost-effectiveness of potential responses to future high levels of transmitted HIV drug resistance in antiretroviral drug-naive populations beginning treatment: modelling study and economic analysisAndrew N Phillips, Valentina Cambiano, Alec Miners, et al.
The Lancet. HIV|September 16, 2023
Checklist for studies of HIV drug resistance prevalence or incidence: rationale and recommended useLawrence Mbuagbaw, Cristian Garcia, Bluma Brenner, et al.
Plos One|March 20, 2013
Medication possession ratio associated with short-term virologic response in individuals initiating antiretroviral therapy in NamibiaSteven Y Hong, Logan Jerger, Anna Jonas, et al.
The Journal of Infectious Diseases|November 17, 2020
Clinical Impact of Pretreatment Human Immunodeficiency Virus Drug Resistance in People Initiating Nonnucleoside Reverse Transcriptase Inhibitor-Containing Antiretroviral Therapy: A Systematic Review and Meta-analysisSilvia Bertagnolio, Lucas Hermans, Michael R Jordan, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 8, 2015
Population-based surveillance of HIV drug resistance emerging on treatment and associated factors at sentinel antiretroviral therapy sites in NamibiaSteven Y Hong, Anna Jonas, Michael DeKlerk, et al.
AIDS (London, England)|August 8, 2013
Averted HIV infections due to expanded antiretroviral treatment eligibility offsets risk of transmitted drug resistance: a modeling studyBrooke E Nichols, Kim C E Sigaloff, Cissy Kityo, et al.
AIDS (London, England)|June 1, 2019
Increasing levels of pretreatment HIV drug resistance and safety concerns for dolutegravir use in women of reproductive ageSeth Chekata Inzaule, Michael R Jordan, Amandine Cournil, et al.
Plos One|February 2, 2017
High Levels of Transmitted HIV Drug Resistance in a Study in Papua New GuineaEvelyn Lavu, Ellan Kave, Euodia Mosoro, et al.
Pageof 11